Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 6/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478505 | 0.96 | ADRB3 (0.47) | ADRB3ADRB1LPAR1SCN9APDE4A | |
| SCHEMBL4458979 | 0.91 | ADRB1 (0.38) | ADRB3ADRB1LPAR1SCN9AROCK2 | |
| SCHEMBL4460136 | 0.89 | ADRB1 (0.42) | ADRB3ADRB1 | |
| SCHEMBL4474494 | 0.87 | ADRB3 (0.47) | ADRB3ADRB1LPAR1ROCK2ROCK1 | |
| SCHEMBL4460048 | 0.87 | ADRB3 (0.44) | ADRB3ADRB1GRM2 | |
| SCHEMBL4463094 | 0.83 | ADRB3 (0.47) | ADRB3ADRB1ROCK2ROCK1 | |
| SCHEMBL6239482 | 0.80 | ADRB1 (0.48) | ADRB3ADRB1SCN9APDE4APDE4B | |
| SCHEMBL4480269 | 0.77 | ADRB3 (0.42) | ADRB3ADRB1 | |
| SCHEMBL6237642 | 0.77 | ADRB3 (0.38) | ADRB3 | |
| SCHEMBL4466360 | 0.76 | ADRB3 (0.55) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| EP-1546086-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004002939-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | WO | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | ADRB3 130/4885ADRB1 39/4885LPAR1 700/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | ADRB3 568/4885ADRB1 256/4885LPAR1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.